ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses

Zheng, Jie; Gu, Jieruo; Su, Yin; Li, Yang; Li, Xingfu; Xiong, Cui; Cao, Hua; Quasny, Holly; Chu, Myron; Curtis, Paula; DeRose, Kathleen; Kurrasch, Regina; Meizlik, Paige; Roth, David A.; Zhang, Fengchun*北京大学; 山东大学; 上海交通大学; 哈尔滨医科大学; 中国医学科学院; 中山大学; 中国医学科学院北京协和医院; 1
Modern Rheumatology2023-7-4DOI: 10.1093/mr/roac076
2被引7阅读
引用收藏
分享

摘要

Objectives To assess belimumab efficacy in patients from North East Asia (NEA) with systemic lupus erythematosus (SLE) in baseline demographic/disease characteristic subgroups. Methods This analysis of patient subgroups from BLISS-NEA (GSK Study 113750; NCT01345253) studied adults with SLE randomized to belimumab (10 mg/kg intravenous) or placebo. Primary endpoint, SLE Responder Index 4 (SRI-4) response rate at Week 52, was analysed in subgroups defined by gender, country, prednisone-equivalent dose, concomitant medications, Safety of Estrogens in Lupus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) score, complement (C) levels, anti-double-stranded deoxyribonucleic acid (dsDNA) positivity, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index score. Results Patients (overall population: N = 677; belimumab: n = 451, placebo: n = 226) were from China (76.4%), Korea (14.8%), and Japan (8.9%). The mean age was 32.1 years; 92.9% were female. In the overall population, more belimumab (53.8%) than placebo (40.1%) patients were SRI-4 Week 52 responders (p = .0001). SRI-4 response rates by subgroups were generally consistent with the overall population. A greater response with belimumab was seen in patients with a baseline SELENA-SLEDAI score >= 10 versus <= 9 and patients with low C3/C4 levels and anti-dsDNA positive at baseline versus those 'NOT' (low C3 and/or C4 and anti-dsDNA positive). Conclusions These findings continue to support the efficacy of belimumab in SLE.

学科与关键词

关键词
Autoantibodybiologicalsclinical trialsystemic lupus erythematosus (SLE)
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Modern Rheumatology
发表日期
2023-07-04
卷期
第 33 卷, 第 4 期
页码
751-757
DOI
10.1093/mr/roac076
语言
ENGLISH
成果收录
SCIE
资助标注
GSK [BEL113750]

作者

  • Z

    Zheng, Jie (第一作者)

    rui jin hosp · shanghai jiao tong univ

  • G

    Gu, Jieruo

    sun yat sen univ

查看全部 15 位作者收起作者
  • S

    Su, Yin

    peking univ

  • L

    Li, Yang

    2 · harbin med univ

  • L

    Li, Xingfu

    shandong univ

  • X

    Xiong, Cui

  • C

    Cao, Hua

    rui jin hosp · shanghai jiao tong univ

  • Q

    Quasny, Holly

  • C

    Chu, Myron

  • C

    Curtis, Paula

  • D

    DeRose, Kathleen

  • K

    Kurrasch, Regina

  • M

    Meizlik, Paige

  • R

    Roth, David A.

  • Z

    Zhang, Fengchun (通讯)

    chinese acad med sci · peking union med coll · peking union med coll hosp · 1

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417